Neogen Q4 revenue beats on food safety segment growth
Reuters2026/07/30 11:43
Overview
U.S. food safety solutions firm's fiscal Q4 revenue flat yr/yr, beating analyst expectations
Adjusted EPS and adjusted net income for Q4 beat analyst expectations
Adjusted EBITDA margin rose to 20.2% from 18.0%, aided by cost initiatives and gross margin gains
Outlook
Neogen sees FY27 revenue between $880 mln and $885 mln, including Genomics division contribution
Company expects FY27 adjusted EBITDA of $180 mln to $182 mln, including Genomics division
Neogen guides Q1 FY27 revenue to $207 mln-$209 mln and adjusted EBITDA to about $37 mln
Result Drivers
FOOD SAFETY SEGMENT - Core Food Safety revenue grew 5.8% in Q4, the highest rate since FY23, driven by strong gains in Indicator Testing, Culture Media, and Bacterial and General Sanitation
ANIMAL SAFETY SUPPLY CHAIN - Animal Safety revenue remained down year-over-year but rose 7% sequentially as supply-related challenges were largely resolved
MARGIN IMPROVEMENT - Gross margin and adjusted gross margin rose, helped by favorable product mix and pricing changes
Company press release: ID:nBw5KtZKya
Key Details
Metric |
Beat/Miss |
Actual |
Consensus Estimate |
Q4 Revenue |
Beat |
$225.30 mln |
$212.36 mln (4 Analysts) |
Q4 Adjusted EPS |
Beat |
$0.09 |
-$0.07 (4 Analysts) |
Q4 Loss Per Share |
|
$0.05 |
|
Q4 Adjusted Net Income |
Beat |
$18.70 mln |
-$14.04 mln (4 Analysts) |
Q4 Net Loss |
|
$11.30 mln |
|
Q4 Adjusted EBITDA |
Beat |
$45.40 mln |
$42.23 mln (4 Analysts) |
Q4 Adjusted EBITDA Margin |
|
20.20% |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Neogen Corp is $11.50, about 22.3% above its July 29 closing price of $9.40
Reuters Recommended Reads
July 28 - Ecolab raises annual profit forecast on pricing, high-tech demand
July 29 - Avantor Q2 results beat, raises 2026 outlook
July 29 - Cyclosporiasis cases in Michigan surpass 10,000 in ongoing outbreak
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Goldman Sachs lifts Infineon voting rights to 5.31% from 4.31%
Caxton FY26 EPS falls 3.4% to 162.7 cents; revenue dips 1.8% to R 6.59 billion
Goldman Sachs trims CECONOMY voting rights stake to 5.87% from 6.06%